Understanding CDSCO’s Post-Marketing Surveillance Requirements in India

Introduction

Post-Marketing Surveillance (PMS) is a cornerstone of pharmacovigilance efforts worldwide. In India, the Central Drugs Standard Control Organization (CDSCO) mandates specific post-approval obligations for pharmaceutical companies to ensure continuous monitoring of the safety and effectiveness of marketed drugs. Given India’s rapidly growing pharmaceutical sector and diverse patient population, effective PMS mechanisms are essential to safeguard public health and maintain regulatory compliance.

The CDSCO, through the Pharmacovigilance Programme of India (PvPI) and related legal provisions, has built a system to collect, analyze, and act upon adverse drug reaction (ADR) data. While pre-marketing clinical trials evaluate drug safety in a limited population, post-marketing surveillance captures real-world safety data across diverse demographics and comorbidities. This article explores the regulatory framework, obligations of Market Authorization Holders (MAHs), submission formats, and best practices for effective compliance with PMS requirements in India.

Background / Regulatory Framework

India’s PMS system is grounded in the Drugs and Cosmetics Act, 1940 and Rules, 1945, supported by Schedule Y and further reinforced by the New Drugs and Clinical Trials Rules (NDCTR), 2019. Together, these regulations define the scope, responsibilities, and procedures for PMS in the Indian context.

Historical Evolution of PMS in India

Initially, PMS in India was sporadic, with limited enforcement. The 2010 launch of the Pharmacovigilance Programme of India (PvPI) marked a turning point. The program, coordinated by the Indian Pharmacopoeia Commission (IPC), now includes more than 250 ADR monitoring centers (AMCs) across the country. The 2019 NDCTR has formalized several PMS responsibilities that were previously only partially enforced.

Key CDSCO Mandates

• Spontaneous Reporting: MAHs must report serious adverse events (SAEs) within 15 calendar days of awareness.
• Periodic Safety Update Reports (PSURs): Submission of PSURs is required every 6 months for the first 2 years post-approval and annually for the next 2 years.
• Ongoing Safety Evaluations: CDSCO can mandate additional post-marketing studies if emerging risks are identified.
• Risk Management Plan (RMP): Sponsors of new drugs must submit an RMP as part of the approval and post-approval obligations.

Core Clinical Trial Insights

1. PSUR Format and Submission

The PSUR should follow ICH E2C(R2) format, customized to Indian regulatory requirements. Key components include:

• Patient exposure data (by indication, age, gender, region)
• Summary tabulations of adverse events
• Benefit-risk analysis and safety signals
• Action plans for risk minimization

Sponsors must submit the PSUR both in print and electronic formats to CDSCO’s safety division.

2. Reporting of SAEs and Adverse Events

Per Schedule Y and PvPI guidelines:

• SAEs occurring in India must be reported to CDSCO, Ethics Committee (EC), and sponsor within 14 calendar days of occurrence.
• Non-serious AEs are encouraged to be reported through PvPI’s Vigiflow platform.
• Investigators must record and assess all AEs in Case Report Forms (CRFs) during PMS trials.

3. PvPI and Role of AMCs

The PvPI network, under IPC, collaborates with CDSCO to collect ADR data. AMCs at medical colleges and hospitals record and forward Individual Case Safety Reports (ICSRs) to PvPI. Data is eventually fed into the WHO-Uppsala Monitoring Centre’s global database for signal detection.

4. Post-Marketing Clinical Trials

CDSCO may require the sponsor to conduct additional clinical trials post-approval to evaluate long-term safety, especially for:

• Drugs approved under accelerated review
• Drugs for orphan or rare diseases
• Drugs with known class effects but limited Indian safety data

These trials must be registered on the Clinical Trials Registry of India (CTRI) and follow ICH-GCP principles.

5. Labeling and Package Inserts

Updated safety findings must be reflected in product labeling. As per CDSCO rules:

• Revised labels must highlight new contraindications, warnings, and precautions.
• Sponsors must seek CDSCO approval for updated labels before market implementation.

6. Market Authorization Holder (MAH) Responsibilities

MAHs must:

• Ensure internal SOPs are aligned with CDSCO reporting timelines
• Maintain a pharmacovigilance system master file (PSMF)
• Train staff on AE reporting and signal detection
• Appoint a Qualified Person for Pharmacovigilance (QPPV) in India

7. Digital Tools and Real-World Evidence (RWE)

CDSCO increasingly recognizes the role of electronic health records (EHRs), mobile apps, and ePROs (electronic patient-reported outcomes) in post-marketing safety surveillance. These tools can complement traditional AE reporting methods and improve detection of rare or long-latency side effects.

Best Practices & Preventive Measures

• Develop a robust safety management plan tailored to the Indian regulatory landscape
• Integrate PvPI requirements into global pharmacovigilance systems
• Ensure dual reporting systems for global and local regulatory timelines
• Conduct internal safety audits periodically
• Provide multilingual ADR reporting tools to patients and investigators

Scientific & Regulatory Evidence

• NDCTR 2019, Rule 24: Defines PMS requirements for new drug approvals
• Schedule Y, Appendix XI: SAE reporting forms and timelines
• ICH E2E: Pharmacovigilance Planning
• ICH E2F: Development Safety Update Reports (DSURs)
• PvPI Guidance: National tools and platforms for safety surveillance

Special Considerations

Pediatric and Geriatric Populations

India’s pharmacovigilance system is evolving to include age-specific surveillance. Certain ADRs manifest differently in children and elderly. CDSCO encourages sponsors to stratify safety data by age group in PSURs and ICSRs.

Herbal and Traditional Products

PMS for AYUSH products is still developing. However, any allopathic drug that is co-formulated or co-marketed with AYUSH components must comply with full CDSCO surveillance mandates.

Off-Label Use Surveillance

Sponsors are encouraged to monitor and report AEs related to off-label use in India, especially in oncology and critical care. These data contribute to evolving risk management strategies.

When Sponsors Should Seek Regulatory Advice

• When PSUR results suggest emerging safety concerns
• Prior to submitting substantial label changes based on PMS data
• If the sponsor is mandated to conduct a PMS trial by CDSCO
• Before implementing digital surveillance tools that integrate with PvPI
• When merging global and Indian PMS reporting systems

FAQs

1. What is the timeline for submitting a PSUR in India?

Every 6 months for the first 2 years post-approval, and annually for the next 2 years. This timeline resets upon product renewal or significant label revision.

2. Are spontaneous AE reports from consumers accepted?

Yes. PvPI accepts ADR reports from healthcare professionals, patients, and caregivers. These can be submitted via email, Vigiflow, or toll-free numbers.

3. Can a PSUR be rejected by CDSCO?

Yes, if it lacks essential components, presents data inaccurately, or fails to address known safety concerns. CDSCO may ask for clarification or updated submission.

4. Is it mandatory to have a QPPV in India?

Yes, for all Market Authorization Holders. The QPPV must reside in India and oversee all pharmacovigilance activities including regulatory reporting.

5. What triggers a post-marketing clinical trial mandate?

New safety signals, conditional approvals, insufficient data in Indian populations, or global recalls of related molecules may trigger this requirement.

Conclusion

Post-marketing surveillance is a critical component of India’s regulatory ecosystem, ensuring drug safety beyond the controlled environment of clinical trials. Sponsors and MAHs must adopt a proactive approach to meet CDSCO’s evolving expectations while leveraging digital tools and real-world data to enhance pharmacovigilance outcomes.